Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion’s US subsidiary (Celltrion USA, Inc.) has signed a pharmaceutical contract manufacturing agreement (CMO) worth approx. KRW 678.7B with Eli Lilly and Company.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Other Major Management Matters (Voluntary Disclosure – Major Management Matters of Subsidiary)
- Subsidiary Name: Celltrion USA, Inc. (CEO: Bon-Joong Kim, Main Business: Pharmaceutical Wholesale & Retail)
- Contract Type: Pharmaceutical Contract Manufacturing Agreement
- Contract Counterparty: Eli Lilly and Company
- Contract Amount: KRW 678,707,700,000 (approx. KRW 678.7B / USD 473,000,000)
- Exchange Rate Applied: Initial basic exchange rate on December 31, 2025 (USD/KRW 1,434.90)
- Contract-to-Revenue Ratio:
- Relative to Celltrion Consolidated Revenue: 19.08% (Based on FY2024 consolidated revenue of KRW 3,557,303,554,371)
- Relative to Subsidiary Revenue: 462.53% (Based on FY2024 separate revenue of KRW 146,737,205,542)
- Contract Period: December 31, 2025 ~ December 31, 2029 (Actual supply scheduled to run for 3 years from Q2 2026 to Q1 2029)
- Contract & Decision Date: December 31, 2025
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Supply Commencement in Q2 2026 and Subsidiary Contract Execution Progress
This disclosure details a major CMO agreement worth approx. KRW 678.7B entered into by Celltrion’s US subsidiary, Celltrion USA, with Eli Lilly, making it important to monitor the commencement of actual supply starting in Q2 2026. Tracking the start of deliveries according to schedule is essential to verify contract fulfillment. Execution updates and supply status can be verified through upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports) or subsequent regulatory disclosures.
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
